

ExpreS2ion to Participate in Key Investor and Industry Events in November 2025

Hørsholm, Denmark, 3 November 2025 – ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS ("ExpreS2ion") is pleased to announce its participation in three key upcoming investor events in November 2025: BIO-Europe, the 2025 Interim Report (Q3) Presentation and the BioStock Life Science Summit.

These events represent important opportunities to showcase ExpreS2ion's innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are available on the [Company's website](#) and via the links below. To arrange a meeting at these events, please contact us at partnering@expres2ionbio.com or investor@expres2ionbio.com.

3-5 November 2025 | BIO-Europe

Vienna, Austria

ExpreS2ion will be represented by business development at BIO-Europe 2025, Europe's premier biopharma partnering conference, held at the Vienna Congress and Convention Center from November 3-5, followed by digital partnering sessions November 11-12. [Event details here](#).

13 November 2025 | 2025 Interim Report (Q3) Presentation

Virtual, 11:00 CET

CEO Bent Frandsen and CFO Keith Alexander will present ExpreS2ion's Q3 results and pipeline updates at a live virtual event hosted by H.C. Andersen Capital/Inderes. The session includes a live Q&A and is free for all investors. [Register here](#).

12-13 September 2025 | BioStock Investing in Life Science: From Seed to Success

Lund, Sweden (Presenting 13 September at 14:55 CET)

CEO Bent Frandsen will present ExpreS2ion on 13 November at 14:55 CET during BioStock's annual life science investment forum. The event features key themes including Women's Health, Pharma Partnering, and AI in Healthcare. Attendance is free but limited. [Apply here](#).

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO

Keith Alexander, CFO

E-mail: investor@expres2ionbio.com

About ExpreS2ion

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.